CellCentric
To add a bio or update company history, please click update information.
News from CellCentric
CellCentric
6 May 2026
CellCentric raises a £160m Series D led by Venrock Healthcare Capital Partners for oral drug designed to treat multiple myeloma and other cancers
CellCentric develops inobrodib, an oral drug designed to treat multiple myeloma and other cancers. The treatment is intended to provide a new option for patients, including those who have already undergone multiple lines of therapy.
CellCentric
19 May 2025
CellCentric raises £90m Series C led by RA Capital and Forbion to advance first-in-class cancer drug
CellCentric is developing an oral cancer drug for multiple myeloma that targets a novel biological pathway, with ongoing clinical studies evaluating its use alone and in combination with existing therapies.
CellCentric
- Life Sciences
- Cambridge, United Kingdom
- £250m
- cellcentric.com
- Update Information
More venture news
- 7 Jul 2026
Healome TherapeuticsHealome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
SeedLife Sciences - 6 Jul 2026
Revolver TherapeuticsRevolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins
EquityLife Sciences
